| A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in … J Weber, JA Thompson, O Hamid, D Minor, A Amin, I Ron, R Ridolfi, ... Clinical cancer research 15 (17), 5591-5598, 2009 | 653 | 2009 |
| Metabolic syndrome: updates on pathophysiology and management in 2021 G Fahed, L Aoun, M Bou Zerdan, S Allam, M Bou Zerdan, Y Bouferraa, ... International journal of molecular sciences 23 (2), 786, 2022 | 627 | 2022 |
| Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer F Andre, N Cabioglu, H Assi, JC Sabourin, S Delaloge, A Sahin, K Broglio, ... Annals of oncology 17 (6), 945-951, 2006 | 284 | 2006 |
| EGFR as a clinical marker in glioblastomas and other gliomas FS Saadeh, R Mahfouz, HI Assi The International journal of biological markers 33 (1), 22-32, 2018 | 155 | 2018 |
| Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration … K Fizazi, R Jones, S Oudard, E Efstathiou, F Saad, R De Wit, J De Bono, ... Journal of Clinical Oncology 33 (7), 723, 2015 | 133 | 2015 |
| Immune checkpoint inhibitors in advanced non–small cell lung cancer HI Assi, AO Kamphorst, NM Moukalled, SS Ramalingam Cancer 124 (2), 248-261, 2018 | 112 | 2018 |
| Anxiety, depression and quality of life in breast cancer patients in the levant R Akel, H El Darsa, B Anouti, D Mukherji, S Temraz, R Raslan, A Tfayli, ... Asian Pacific journal of cancer prevention: APJCP 18 (10), 2809, 2017 | 76 | 2017 |
| Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical … R El Sayed, L El Jamal, S El Iskandarani, J Kort, M Abdel Salam, H Assi Frontiers in oncology 9, 510, 2019 | 70 | 2019 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer F Andre, A Khalil, K Slimane, C Massard, MC Mathieu, S Vignot, H Assi, ... Journal of clinical oncology 23 (13), 2996-3000, 2005 | 47 | 2005 |
| Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases H Assi, KS Wilson Current Oncology 20 (2), 165-169, 2013 | 45 | 2013 |
| Prevalence and severity of sleep disturbances among patients with early breast cancer R Fakih, M Rahal, L Hilal, L Hamieh, M Dany, S Karam, L Shehab, ... Indian journal of palliative care 24 (1), 35, 2018 | 44 | 2018 |
| The use of heparin and heparin-like molecules in cancer treatment: a review J Atallah, HH Khachfe, J Berro, HI Assi Cancer treatment and research communications 24, 100192, 2020 | 41 | 2020 |
| Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma JS Weber, D Berman, J Siegel, D Minor, A Amin, JA Thompson, I Ron, ... Journal of Clinical Oncology 26 (15_suppl), 9010-9010, 2008 | 38 | 2008 |
| Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial H Assi, G Missenard, P Terrier, C Le Pechoux, S Bonvalot, D Vanel, ... Current Oncology 17 (6), 23-31, 2010 | 37 | 2010 |
| Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial JA Thompson, O Hamid, D Minor, A Amin, IG Ron, R Ridolfi, H Assi, ... Journal of Immunotherapy 35 (1), 73-77, 2012 | 35 | 2012 |
| Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer A Tfayli, M Al Assaad, G Fakhri, R Akel, H Atwi, H Ghanem, F El Karak, ... Cancer medicine 9 (22), 8406-8411, 2020 | 33 | 2020 |
| Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis S Temraz, A Shamseddine, D Mukherji, M Charafeddine, A Tfayli, H Assi, ... Pathology & Oncology Research 25, 1059-1066, 2019 | 30 | 2019 |
| Mechanisms of immunotoxicity: stressors and evaluators M Bou Zerdan, S Moussa, A Atoui, HI Assi International Journal of Molecular Sciences 22 (15), 8242, 2021 | 29 | 2021 |
| Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib B Melosky, J Agulnik, H Assi Current Oncology 15 (6), 279-285, 2008 | 28 | 2008 |
